Sangamo Therapeutics Incorporated (NASDAQ:SGMO) had a decrease of 6.75% in short interest. SGMO’s SI was 7.64M shares in April as released by FINRA. Its down 6.75% from 8.19 million shares previously. With 716,800 avg volume, 11 days are for Sangamo Therapeutics Incorporated (NASDAQ:SGMO)’s short sellers to cover SGMO’s short positions. The SI to Sangamo Therapeutics Incorporated’s float is 11.57%. About 83,187 shares traded. Sangamo Therapeutics Inc (NASDAQ:SGMO) has declined 9.57% since September 14, 2016 and is downtrending. It has underperformed by 20.40% the S&P500.
In a research note revealed to investors and clients on today, Numis Securities kept their Buy rating on Acacia Mining (LON:ACA)‘s stock. The price target indicates a potential upside of 45.28% from firm’s current price.
Among 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 have Buy rating, 1 Sell and 4 Hold. Therefore 44% are positive. Sangamo Biosciences had 12 analyst reports since August 8, 2015 according to SRatingsIntel. The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) has “Buy” rating given on Thursday, September 3 by JP Morgan. On Friday, September 4 the stock rating was maintained by Cowen & Co with “Buy”. Janney Capital downgraded the shares of SGMO in report on Thursday, August 4 to “Neutral” rating. The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) has “Neutral” rating given on Tuesday, November 1 by Wedbush. The rating was downgraded by Zacks on Tuesday, September 8 to “Sell”. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report. The firm has “Buy” rating by Jefferies given on Wednesday, September 2. The rating was maintained by Wedbush with “Buy” on Wednesday, September 2. Piper Jaffray downgraded Sangamo Therapeutics Inc (NASDAQ:SGMO) on Wednesday, October 19 to “Neutral” rating. The stock has “Overweight” rating by JP Morgan on Saturday, August 8.
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The company has market cap of $304.76 million. The Firm is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. It currently has negative earnings. The Firm has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development.
Investors sentiment decreased to 1.15 in Q4 2016. Its down 0.06, from 1.21 in 2016Q3. It dropped, as 17 investors sold Sangamo Therapeutics Inc shares while 31 reduced holdings. 18 funds opened positions while 37 raised stakes. 39.96 million shares or 8.31% less from 43.58 million shares in 2016Q3 were reported. Price T Rowe Associates Md holds 143,200 shares or 0% of its portfolio. Sabby Management Limited reported 63,204 shares. 45,823 are owned by Barclays Public Ltd. Dimensional Fund Advisors Lp owns 128,251 shares for 0% of their portfolio. United Cap Fincl Advisers Limited Co reported 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO). Jpmorgan Chase Communication owns 0% invested in Sangamo Therapeutics Inc (NASDAQ:SGMO) for 1,320 shares. Geode Cap Mngmt invested in 0% or 614,633 shares. Highlander Cap Management Ltd Liability Com holds 0.05% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO) for 17,500 shares. Hanson Mcclain holds 1,000 shares. Bnp Paribas Arbitrage owns 1,213 shares for 0% of their portfolio. Fic Cap holds 1.34% or 875,284 shares in its portfolio. Da Davidson Co holds 0% or 5,751 shares in its portfolio. Brick & Kyle Assocs accumulated 1,100 shares. Alliancebernstein Ltd Partnership stated it has 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO). Wells Fargo And Mn invested 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO).
Acacia Mining plc is primarily engaged in the business of mining, processing and sale of gold. The company has market cap of 1.70 billion GBP. The Firm has three operating mines located in Tanzania. It has a 22.86 P/E ratio. The Company’s divisions are North Mara gold mine, Bulyanhulu gold mine and Buzwagi gold mine.
Among 22 analysts covering Acacia Mining Plc (LON:ACA), 10 have Buy rating, 4 Sell and 8 Hold. Therefore 45% are positive. Acacia Mining Plc has GBX 720 highest and GBX 168 lowest target. GBX 413.85’s average target is 0.08% above currents GBX 413.5 stock price. Acacia Mining Plc had 206 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Acacia Mining PLC (LON:ACA) earned “Outperform” rating by Credit Suisse on Monday, September 14. The stock has “Buy” rating by UBS on Friday, February 12. JP Morgan maintained Acacia Mining PLC (LON:ACA) rating on Friday, April 22. JP Morgan has “Overweight” rating and GBX 310 target. Investec upgraded Acacia Mining PLC (LON:ACA) rating on Friday, October 30. Investec has “Buy” rating and GBX 244 target. On Monday, August 10 the stock rating was downgraded by Investec to “Hold”. Credit Suisse maintained Acacia Mining PLC (LON:ACA) rating on Wednesday, December 7. Credit Suisse has “Outperform” rating and GBX 625 target. Panmure Gordon downgraded it to “Hold” rating and GBX 400 target in Friday, September 16 report. The rating was maintained by Bank of America on Wednesday, November 25 with “Neutral”. The stock of Acacia Mining PLC (LON:ACA) earned “Sell” rating by Citigroup on Wednesday, May 18. Investec maintained the stock with “Hold” rating in Wednesday, October 7 report.